Eli Keshavarz-Moore

Dr. Eli Keshavarz-Moore


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2017 in Microbial Cell Factories
Verified
Journal Article
Open access
PDF file
AGAnna Gąciarz
Anna Gąciarz
NKNarendar Kumar Khatri
Narendar Kumar Khatri
MVM. Lourdes Velez-Suberbie
M. Lourdes Velez-Suberbie
MSMirva Saaranen
Mirva Saaranen
YUYuko Uchida
Yuko Uchida
LRLloyd W. Ruddock
Lloyd W. Ruddock
The production of recombinant proteins containing disulfide bonds in Escherichia coli is challenging. In most cases the protein of interest needs to be either targeted to the oxidizing periplasm or expressed in the cytoplasm in the form of inclusion bodies, then solubilized and re-folded in vitro. Both of these approaches have limitations. Previously we showed that soluble expression of disulfide bonded proteins in the cytoplasm of E. coli is possible at shake flask scale with a system, known as CyDisCo, which is based on co-expression of a protein of interest along with a sulfhydryl oxidase and a disulfide bond isomerase. With CyDisCo it is possible to produce disulfide bonded proteins in the presence of intact reducing pathways in the cytoplasm. Here we scaled up production of four disulfide bonded proteins to stirred tank bioreactors and achieved high cell densities and protein yields in glucose fed-batch fermentations, using an E. coli strain (BW25113) with the cytoplasmic reducing pathways intact. Even without process optimization production of purified human single chain IgA1 antibody fragment reached 139 mg/L and hen avidin 71 mg/L, while purified yields of human growth hormone 1 and interleukin 6 were around 1 g/L. Preliminary results show that human growth hormone 1 was also efficiently produced in fermentations of W3110 strain and when glucose was replaced with glycerol as the carbon source. Our results show for the first time that efficient production of high yields of soluble disulfide bonded proteins in the cytoplasm of E. coli with the reducing pathways intact is feasible to scale-up to bioreactor cultivations on chemically defined minimal media.

1 June 2013 in Biotechnology and Bioprocess Engineering
Verified
Journal Article
Closed access
PDF file
SBSteven D. Branston
Steven D. Branston
ESEmma C. Stanley
Emma C. Stanley
JWJohn M. Ward
John M. Ward
EKEli Keshavarz-Moore
Eli Keshavarz-Moore

27 February 2015 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
SBSteven D. Branston
Steven D. Branston
JWJason Wright
Jason Wright
EKEli Keshavarz-Moore
Eli Keshavarz-Moore

27 July 2017 in Biotechnology Progress
Verified
Journal Article
Open access
PDF file
MVM. Lourdes Velez‐Suberbie
M. Lourdes Velez‐Suberbie
JBJohn P. J. Betts
John P. J. Betts
KWKelly L. Walker
Kelly L. Walker
CRColin Robinson
Colin Robinson
BZBarney Zoro
Barney Zoro
EKEli Keshavarz-Moore
Eli Keshavarz-Moore
High throughput automated fermentation systems have become a useful tool in early bioprocess development. In this study, we investigated a 24 x 15 mL single use microbioreactor system, ambr 15f, designed for microbial culture. We compared the fed‐batch growth and production capabilities of this system for two Escherichia coli strains, BL21 (DE3) and MC4100, and two industrially relevant molecules, hGH and scFv. In addition, different carbon sources were tested using bolus, linear or exponential feeding strategies, showing the capacity of the ambr 15f system to handle automated feeding. We used power per unit volume (P/V) as a scale criterion to compare the ambr 15f with 1 L stirred bioreactors which were previously scaled‐up to 20 L with a different biological system, thus showing a potential 1,300 fold scale comparability in terms of both growth and product yield. By exposing the cells grown in the ambr 15f system to a level of shear expected in an industrial centrifuge, we determined that the cells are as robust as those from a bench scale bioreactor. These results provide evidence that the ambr 15f system is an efficient high throughput microbial system that can be used for strain and molecule selection as well as rapid scale‐up. © 2017 The Authors Biotechnology Progress published by Wiley Periodicals, Inc. on behalf of American Institute of Chemical Engineers Biotechnol. Prog., 34:58–68, 2018

31 August 2021 in Bioengineering
Verified
Journal Article
Open access
PDF file
SMSalomé de Sá Magalhães
Salomé de Sá Magalhães
EKEli Keshavarz-Moore
Eli Keshavarz-Moore
Vaccination is of paramount importance to global health. With the advent of the more recent pandemics, the urgency to expand the range has become even more evident. However, the potential limited availability and affordability of vaccines to resource low- and middle-income countries has created a need for solutions that will ensure cost-effective vaccine production methods for these countries. Pichia pastoris (P. pastoris) (also known as Komagataella phaffii) is one of the most promising candidates for expression of heterologous proteins in vaccines development. It combines the speed and ease of highly efficient prokaryotic platforms with some key capabilities of mammalian systems, potentially reducing manufacturing costs. This review will examine the latest developments in P. pastoris from cell engineering and design to industrial production systems with focus on vaccine development and with reference to specific key case studies.

10 October 2011 in Journal of Biotechnology
Verified
Journal Article
Closed access
ADArjun Dhanoya
Arjun Dhanoya
BCBenjamin M. Chain
Benjamin M. Chain
EKEli Keshavarz-Moore
Eli Keshavarz-Moore